Idiopathic pulmonary fibrosis overview: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
(15 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Idiopathic pulmonary fibrosis }}
{{Idiopathic pulmonary fibrosis}}
{{CMG}}
{{CMG}}; {{AE}} {{AEL}}  
==Overview==
==Overview==
''' [[Idiopathic]] Pulmonary Fibrosis (IPF)''', is a chronic progressive interstitial lung disease of unknown etiology. It is one of the two classic interstitial lung diseases, the other being sarcoidosis.<ref name="WMMT">{{cite book |title=The Washington Manual of Medical Therapeutics |last=Cooper |first=Daniel H. |coauthors=Andrew J. Krainik, Sam J. Lubner, Hilary E. L. Reno (eds.)|edition=32nd edition |publisher=Lippincott Williams & Wilkins |pages=276 |isbn=978-0781781251}}</ref>
Idiopathic pulmonary fibrosis (IPF) is a progressive [[Fibrosis|fibrosing disease]] of the [[Interstitial lung disease|interstitial lung diseases]] which leads to irreversible decline in the [[lung]] functions for unknown cause. IPF is one of the interstitial lung disease and particularly is a subtype of [[idiopathic interstitial pneumonia]]. Pulmonary fibrosis share the pathogenesis process of interstitial lung disease which involve the pulmonary [[parenchyma]]. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary [[tissue]] injury. The main features of the lung injury includes [[inflammation]], [[fibrosis]], and [[granulomas]] development. Common causes of pulmonary fibrosis include [[autoimmunity]], [[rheumatoid arthritis]], [[scleroderma]], [[tuberculosis]], [[SLE]], [[sarcoidosis]], and [[polymyositis]]. Other causes of pulmonary fibrosis include environmental factors as [[cigarette smoking]] and [[dust]] exposure. Idiopathic pulmonary fibrosis must be differentiated from other causes of interstitial lung diseases which may cause fibrosis as well. Prevalence of idiopathic pulmonary fibrosis ranges from a low of 0.5 per 100.000 persons to a high of 27.9 per 100.000. Incidence of idiopathic pulmonary fibrosis ranges from a low of 3 per 100,000 persons to a high of 9 per 100,000 persons. Common risk factors of pulmonary fibrosis include cigarette smoking and genetic mutations which include ''hTERT, [[MUC5B]]'', ''[[TERT]], and RTEL1.'' Other risk factors include GERD and wood dust. If left untreated, idiopathic pulmonary fibrosis will lead to complete [[respiratory failure]] and death. Common complications of idiopathic pulmonary fibrosis include [[pulmonary hypertension]], [[lung cancer]], and [[cardiovascular]] comorbidities. The prognosis of idiopathic pulmonary fibrosis is usually poor with a survival rate from 2 to 5 years. Common symptoms of idiopathic pulmonary fibrosis include [[Dyspnea]], [[cough]], [[Clubbing]], [[Crackles]], and [[arthralgia]]. Physical examination of patients with occupational lung disease is usually remarkable for [[bronchial]] breathing, increased vocal [[resonance]], and fine [[crepitations]]. On chest CT scan, Idiopathic pulmonary fibrosis is characterized by honeycombing appearance of the [[lungs]], [[bronchiectasis]], ground glass opacities, and distortion of the lung opacities. The mainstay of the therapy is supportive care measures as [[mechanical ventilation]]. [[Lung transplantation]] is essential in treatment of patients with idiopathic pulmonary fibrosis. [[Pulmonary fibrosis]] is the most common interstitial lung disease requiring lung transplant and it should be performed early in order to increase the survival rate.


More specifically, '''IPF''' is defined as a distinctive type of ''chronic fibrosing interstitial pneumonia'' of unknown cause associated with a histological pattern of [[usual interstitial pneumonia]] (UIP).<ref name="ATS">{{cite journal |url=http://ajrccm.atsjournals.org/cgi/content/full/161/2/646 |title=Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment |journal=American Journal of Respiratory and Critical Care Medicine |volume=161 |number=2 |month=February |year=2000 |pages=646-664}}</ref>
==Historical Perspective==
Pulmonary fibrosis was first described by Dr. Von Buhl in 1872. Dr. Rindfleish reported a case of a 40 year old patient who presented with worsening [[cough]] and [[dyspnea]] and he named this case as "Cirrhosis cystica pulmonum" in 1898.


==Historical Perspective==
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
==Classification==
==Classification==
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
Idiopathic pulmonary fibrosis is a disease among a large group of the interstitial lung diseases and particularly a subtype of the idiopathic interstitial pneumonia. The major group Acute Interstitial Pneumonia (AIP), Cryptogenic Organizing Pneumonia (COP), Respiratory Bronchiolitis–Interstitial Lung Disease (RB-ILD), and Desquamative Interstitial Pneumonia (DIP).
:*[group1]
 
:*[group2]
:*[group3]
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
==Pathophysiology==
==Pathophysiology==
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
Pulmonary fibrosis share the pathogenesis process of [[interstitial lung disease]] which involve the pulmonary [[parenchyma]]. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary [[tissue]] injury. The main features of the lung injury includes [[inflammation]], [[fibrosis]], and [[granulomas]] development.
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
 
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Causes==
==Causes==
* [Disease name] may be caused by either [cause1], [cause2], or [cause3].
Common causes of pulmonary fibrosis include [[autoimmunity]], [[rheumatoid arthritis]], [[scleroderma]], [[tuberculosis]], [[SLE]], [[sarcoidosis]], and [[polymyositis]]. Other causes of pulmonary fibrosis include environmental factors as [[cigarette smoking]] and dust exposure.
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
 
* There are no established causes for [disease name].
==Differentiating Idiopathic Pulmonary Fibrosis from Other Diseases==
Idiopathic pulmonary fibrosis must be differentiated from other causes of interstitial lung diseases which may cause [[fibrosis]] as well. Other diseases may include acute interstitial pneumonia, hypersensitivity [[pneumonia]], [[Occupational lung disease|occupational lung diseases]], and pulmonary hemorrhage diseases.
==Differentiating [disease name] from other Diseases==
 
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
:*[Differential dx1]
:*[Differential dx2]
:*[Differential dx3]
==Epidemiology and Demographics==
==Epidemiology and Demographics==
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
Prevalence of idiopathic pulmonary fibrosis ranges from a low of 0.5 per 100.000 persons to a high of 27.9 per 100.000. Incidence of idiopathic pulmonary fibrosis ranges from a low of 3 per 100,000 persons to a high of 9 per 100,000 persons. The prevalence of idiopathic pulmonary fibrosis increases with age. Idiopathic pulmonary fibrosis is more prevalent in men more than women.
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
 
===Age===
*Patients of all age groups may develop [disease name].
*[Disease name] is more commonly observed among patients aged [age range] years old.
*[Disease name] is more commonly observed among [elderly patients/young patients/children].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected with [disease name] than [gender 2].
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
===Race===
*There is no racial predilection for [disease name].
*[Disease name] usually affects individuals of the [race 1] race.
*[Race 2] individuals are less likely to develop [disease name].
==Risk Factors==
==Risk Factors==
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Common risk factors of pulmonary fibrosis include [[cigarette smoking]] and [[genetic mutations]] which include ''hTERT, [[MUC5B]]'', ''[[TERT]], and RTEL1.'' Other risk factors include [[GERD]] and wood dust. 
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
== Diagnosis ==
===Diagnostic Criteria===
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
:*[criterion 1]
:*[criterion 2]
:*[criterion 3]
:*[criterion 4]
=== Symptoms ===
*[Disease name] is usually asymptomatic.
*Symptoms of [disease name] may include the following:
:*[symptom 1]
:*[symptom 2]
:*[symptom 3]
:*[symptom 4]
:*[symptom 5]
:*[symptom 6]
=== Physical Examination ===
*Patients with [disease name] usually appear [general appearance].
*Physical examination may be remarkable for:
:*[finding 1]
:*[finding 2]
:*[finding 3]
:*[finding 4]
:*[finding 5]
:*[finding 6]
=== Laboratory Findings ===
*There are no specific laboratory findings associated with [disease name].


*A  [positive/negative] [test name] is diagnostic of [disease name].
==Screening==
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
There is insufficient evidence to recommend routine screening for idiopathic pulmonary fibrosis.
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*[Imaging study 1] is the imaging modality of choice for [disease name].
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
== Treatment ==
=== Medical Therapy ===
*There is no treatment for [disease name]; the mainstay of therapy is supportive care.
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
*[Medical therapy 1] acts by [mechanism of action 1].
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
=== Surgery ===
*Surgery is the mainstay of therapy for [disease name].
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
=== Prevention ===
*There are no primary preventive measures available for [disease name].
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].


*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].  
==Natural History, Complications, and Prognosis==
 
If left untreated, idiopathic pulmonary fibrosis will lead to complete [[respiratory failure]] and death. Common complications of idiopathic pulmonary fibrosis include [[pulmonary hypertension]], [[lung cancer]], and [[cardiovascular]] comorbidities. The prognosis of idiopathic pulmonary fibrosis is usually poor with a survival rate from 2 to 5 years.
==Diagnosis==
===Diagnostic Study of Choice===
The diagnostic criteria for IPF includes major criteria and minor criteria. The major criteria must include exclusion of other causes of [[interstitial lung disease]], pulmonary function tests that is evident of lung [[fibrosis]], bibasilar [[reticular]] abnormalities in CT lung, and lung biopsy shows [[fibrosis]]. The minor criteria should include 3 of 4 criterion as age > 50, duration of illness more than 3 months, bibasilar inspiratory [[crackles]], and insidious onset of [[exertional dyspnea]].
 
===History and Symptoms===
Common symptoms of idiopathic pulmonary fibrosis include [[Dyspnea]], [[cough]], [[Clubbing]], [[Crackles]], and [[arthralgia]]. Less common symptoms include [[Hamman-Rich Syndrome]].
 
===Physical Examination===
Patients with idiopathic pulmonary fibrosis usually appear [[Fatigue|fatigued]] and [[short of breath]]. Physical examination of patients with idiopathic pulmonary fibrosis is usually remarkable for bronchial breathing, increased vocal resonance, and fine [[crepitations]].
 
===Laboratory Findings===
There are no diagnostic laboratory findings associated with [[Idiopathic pulmonary fibrosis|pulmonary fibrosis]]. However, useful laboratory findings consistent with the diagnosis of pulmonary fibrosis include abnormal [[Arterial blood gas|arterial blood gases]], [[sputum]] analysis, and [[Complete blood count|blood picture]].
 
===X-ray===
X ray imaging does not show specific features for idiopathic pulmonary fibrosis. However, patients with idiopathic pulmonary fibrosis have imaging abnormalities from the beginning of the disease course.
 
===CT scan===
On chest CT scan, Idiopathic pulmonary fibrosis is characterized by honeycombing appearance of the [[lungs]], [[bronchiectasis]], ground glass opacities, and distortion of the lung opacities.
 
===MRI===
There are no MRI findings associated with idiopathic pulmonary fibrosis.
 
===Other Imaging Findings===
There are no other imaging findings associated with idiopathic pulmonary fibrosis.
 
===Other Diagnostic Studies===
Other diagnsotic findings consistent with diagnosis of idiopathic pulmonary fibrosis include reduced [[lung volumes]] and decreased [[DLCO|diffusion capacity of carbon monoxide]]. Both are performed via [[spirometry]].
 
==Treatment==
===Medical Therapy===
The mainstay of therapy for idiopathic pulmonary fibrosis is the supportive care measures which include [[mechanical ventilation]], [[pulmonary rehabilitation]], and [[vaccination]] against [[influenza]] and [[pneumococcus]]. Medical treatment as [[nintedanib]] and [[pirfenidone]] can be administrated to slow the disease progression.
 
===Surgery===
[[Lung transplantation]] is essential in treatment of patients with idiopathic pulmonary fibrosis. [[Pulmonary fibrosis]] is the most common interstitial lung disease requiring lung transplant and it should be performed early in order to increase the survival rate.
 
===Primary Prevention===
The primary prevention of pulmonary fibrosis or usual interstitial pneumonia includes [[smoking cessation]] and [[vaccination]] against [[influenza]].
 
===Secondary Prevention===
The primary and secondary prevention strategies for idiopathic pulmonary fibrosis are the same.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}


[[Category:Pulmonology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 18:37, 9 April 2018

Idiopathic pulmonary fibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic pulmonary fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic pulmonary fibrosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Idiopathic pulmonary fibrosis overview

CDC on Idiopathic pulmonary fibrosis overview

Idiopathic pulmonary fibrosis overview in the news

Blogs on Idiopathic pulmonary fibrosis overview

Directions to Hospitals Treating Idiopathic pulmonary fibrosis

Risk calculators and risk factors for Idiopathic pulmonary fibrosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing disease of the interstitial lung diseases which leads to irreversible decline in the lung functions for unknown cause. IPF is one of the interstitial lung disease and particularly is a subtype of idiopathic interstitial pneumonia. Pulmonary fibrosis share the pathogenesis process of interstitial lung disease which involve the pulmonary parenchyma. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary tissue injury. The main features of the lung injury includes inflammation, fibrosis, and granulomas development. Common causes of pulmonary fibrosis include autoimmunity, rheumatoid arthritis, scleroderma, tuberculosis, SLE, sarcoidosis, and polymyositis. Other causes of pulmonary fibrosis include environmental factors as cigarette smoking and dust exposure. Idiopathic pulmonary fibrosis must be differentiated from other causes of interstitial lung diseases which may cause fibrosis as well. Prevalence of idiopathic pulmonary fibrosis ranges from a low of 0.5 per 100.000 persons to a high of 27.9 per 100.000. Incidence of idiopathic pulmonary fibrosis ranges from a low of 3 per 100,000 persons to a high of 9 per 100,000 persons. Common risk factors of pulmonary fibrosis include cigarette smoking and genetic mutations which include hTERT, MUC5B, TERT, and RTEL1. Other risk factors include GERD and wood dust. If left untreated, idiopathic pulmonary fibrosis will lead to complete respiratory failure and death. Common complications of idiopathic pulmonary fibrosis include pulmonary hypertension, lung cancer, and cardiovascular comorbidities. The prognosis of idiopathic pulmonary fibrosis is usually poor with a survival rate from 2 to 5 years. Common symptoms of idiopathic pulmonary fibrosis include DyspneacoughClubbingCrackles, and arthralgia. Physical examination of patients with occupational lung disease is usually remarkable for bronchial breathing, increased vocal resonance, and fine crepitations. On chest CT scan, Idiopathic pulmonary fibrosis is characterized by honeycombing appearance of the lungsbronchiectasis, ground glass opacities, and distortion of the lung opacities. The mainstay of the therapy is supportive care measures as mechanical ventilation. Lung transplantation is essential in treatment of patients with idiopathic pulmonary fibrosis. Pulmonary fibrosis is the most common interstitial lung disease requiring lung transplant and it should be performed early in order to increase the survival rate.

Historical Perspective

Pulmonary fibrosis was first described by Dr. Von Buhl in 1872. Dr. Rindfleish reported a case of a 40 year old patient who presented with worsening cough and dyspnea and he named this case as "Cirrhosis cystica pulmonum" in 1898.

Classification

Idiopathic pulmonary fibrosis is a disease among a large group of the interstitial lung diseases and particularly a subtype of the idiopathic interstitial pneumonia. The major group Acute Interstitial Pneumonia (AIP), Cryptogenic Organizing Pneumonia (COP), Respiratory Bronchiolitis–Interstitial Lung Disease (RB-ILD), and Desquamative Interstitial Pneumonia (DIP).

Pathophysiology

Pulmonary fibrosis share the pathogenesis process of interstitial lung disease which involve the pulmonary parenchyma. Although the exact pathogenesis is not fully understood, there are many initiating factors which cause the pulmonary tissue injury. The main features of the lung injury includes inflammation, fibrosis, and granulomas development.

Causes

Common causes of pulmonary fibrosis include autoimmunity, rheumatoid arthritis, scleroderma, tuberculosis, SLE, sarcoidosis, and polymyositis. Other causes of pulmonary fibrosis include environmental factors as cigarette smoking and dust exposure.

Differentiating Idiopathic Pulmonary Fibrosis from Other Diseases

Idiopathic pulmonary fibrosis must be differentiated from other causes of interstitial lung diseases which may cause fibrosis as well. Other diseases may include acute interstitial pneumonia, hypersensitivity pneumonia, occupational lung diseases, and pulmonary hemorrhage diseases.

Epidemiology and Demographics

Prevalence of idiopathic pulmonary fibrosis ranges from a low of 0.5 per 100.000 persons to a high of 27.9 per 100.000. Incidence of idiopathic pulmonary fibrosis ranges from a low of 3 per 100,000 persons to a high of 9 per 100,000 persons. The prevalence of idiopathic pulmonary fibrosis increases with age. Idiopathic pulmonary fibrosis is more prevalent in men more than women.

Risk Factors

Common risk factors of pulmonary fibrosis include cigarette smoking and genetic mutations which include hTERT, MUC5B, TERT, and RTEL1. Other risk factors include GERD and wood dust. 

Screening

There is insufficient evidence to recommend routine screening for idiopathic pulmonary fibrosis.

Natural History, Complications, and Prognosis

If left untreated, idiopathic pulmonary fibrosis will lead to complete respiratory failure and death. Common complications of idiopathic pulmonary fibrosis include pulmonary hypertension, lung cancer, and cardiovascular comorbidities. The prognosis of idiopathic pulmonary fibrosis is usually poor with a survival rate from 2 to 5 years.

Diagnosis

Diagnostic Study of Choice

The diagnostic criteria for IPF includes major criteria and minor criteria. The major criteria must include exclusion of other causes of interstitial lung disease, pulmonary function tests that is evident of lung fibrosis, bibasilar reticular abnormalities in CT lung, and lung biopsy shows fibrosis. The minor criteria should include 3 of 4 criterion as age > 50, duration of illness more than 3 months, bibasilar inspiratory crackles, and insidious onset of exertional dyspnea.

History and Symptoms

Common symptoms of idiopathic pulmonary fibrosis include DyspneacoughClubbingCrackles, and arthralgia. Less common symptoms include Hamman-Rich Syndrome.

Physical Examination

Patients with idiopathic pulmonary fibrosis usually appear fatigued and short of breath. Physical examination of patients with idiopathic pulmonary fibrosis is usually remarkable for bronchial breathing, increased vocal resonance, and fine crepitations.

Laboratory Findings

There are no diagnostic laboratory findings associated with pulmonary fibrosis. However, useful laboratory findings consistent with the diagnosis of pulmonary fibrosis include abnormal arterial blood gasessputum analysis, and blood picture.

X-ray

X ray imaging does not show specific features for idiopathic pulmonary fibrosis. However, patients with idiopathic pulmonary fibrosis have imaging abnormalities from the beginning of the disease course.

CT scan

On chest CT scan, Idiopathic pulmonary fibrosis is characterized by honeycombing appearance of the lungsbronchiectasis, ground glass opacities, and distortion of the lung opacities.

MRI

There are no MRI findings associated with idiopathic pulmonary fibrosis.

Other Imaging Findings

There are no other imaging findings associated with idiopathic pulmonary fibrosis.

Other Diagnostic Studies

Other diagnsotic findings consistent with diagnosis of idiopathic pulmonary fibrosis include reduced lung volumes and decreased diffusion capacity of carbon monoxide. Both are performed via spirometry.

Treatment

Medical Therapy

The mainstay of therapy for idiopathic pulmonary fibrosis is the supportive care measures which include mechanical ventilation, pulmonary rehabilitation, and vaccination against influenza and pneumococcus. Medical treatment as nintedanib and pirfenidone can be administrated to slow the disease progression.

Surgery

Lung transplantation is essential in treatment of patients with idiopathic pulmonary fibrosis. Pulmonary fibrosis is the most common interstitial lung disease requiring lung transplant and it should be performed early in order to increase the survival rate.

Primary Prevention

The primary prevention of pulmonary fibrosis or usual interstitial pneumonia includes smoking cessation and vaccination against influenza.

Secondary Prevention

The primary and secondary prevention strategies for idiopathic pulmonary fibrosis are the same.

References


Template:WikiDoc Sources